Pharnext Aktie - ALPHA

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,0002

Gebot

0,0002

Fragen

0,0002

Volumen

0,00

0,00 Tagesbereich 0,00

0,0001 52-Wochen-Bereich 1,10

Marktkapitalisierung

17,505

Handelsende

0,0002

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

0,00

Ausgegebene Aktien

87.525

Dividendenrendite

Kurs-Gewinn-Verhältnis

-79.519,02

Gewinn pro Aktie (EPS)

-314,39

Erlöse

174k

Nettogewinn

-27,52M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

pharnext.com/

Hauptsitz

Suresnes, Hauts-de-seine, Fra

Gegründet

Pharnext is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALPHA. The last closing price for Pharnext was 0,00 €. Over the last year, Pharnext shares have traded in a share price range of 0,0001 € to 1,10 €.

Pharnext currently has 87.525 shares in issue. The market capitalisation of Pharnext is 17,51 € . Pharnext has a price to earnings ratio (PE ratio) of -79519.02.

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday...

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New Data from the...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

Diese Zustimmung bereitet den Weg für die Stellung eines Marktzulassungsantrags in Europa Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), ein biopharmazeutisches Unternehmen und...

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a...

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter eines neuen Ansatzes zur Entwicklung innovativer Medikamentenkombinationen, die auf Big...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0.0002	0.0002	0.0002	0	0	DE
4	0	0	0.0002	0.0002	0.0002	0	0	DE
12	0	0	0.0002	0.0002	0.0002	0	0	DE
26	-0.0008	-80	0.001	0.001	0.0001	2669548	0.00022897	DE
52	0	0	0.0002	1.1	0.0001	9078506	0.00068158	DE
156	-0.1138	-99.8245614035	0.114	1.95	0.0001	60943446	0.00240744	DE
260	-5.9398	-99.9966329966	5.94	6.68	0.0001	38035979	0.00715358	DE

ALPHA - Frequently Asked Questions (FAQ)

What is the current Pharnext share price?

The current share price of Pharnext is 0,0002 €

How many Pharnext shares are in issue?

Pharnext has 87.525 shares in issue

What is the market cap of Pharnext?

The market capitalisation of Pharnext is EUR 17,51

What is the 1 year trading range for Pharnext share price?

Pharnext has traded in the range of 0,0001 € to 1,10 € during the past year

What is the PE ratio of Pharnext?

The price to earnings ratio of Pharnext is -79,52k

What is the cash to sales ratio of Pharnext?

The cash to sales ratio of Pharnext is 12,58M

What is the reporting currency for Pharnext?

Pharnext reports financial results in EUR

What is the latest annual turnover for Pharnext?

The latest annual turnover of Pharnext is EUR 174k

What is the latest annual profit for Pharnext?

The latest annual profit of Pharnext is EUR -27,52M

What is the registered address of Pharnext?

The registered address for Pharnext is 14 RUE DE LA REPUBLIQUE, SURESNES, HAUTS-DE-SEINE, 92150

What is the Pharnext website address?

The website address for Pharnext is pharnext.com/

Which industry sector does Pharnext operate in?

Pharnext operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
DMSBSDiagnostic Medical Systems	0,007 € (75,00%)	36,27k
POXELPoxel	0,3905 € (60,04%)	6,13M
GTRDSGroupe Tera DS	0,12 € (43,71%)	32,95k
MCPGrupo Media Capital Sgps Sa	2,00 € (23,46%)	5
ALDOLDolfines	4,12 € (21,00%)	82,74k
DRVDSDrone Volt DS	0,0009 € (-50,00%)	707,14k
HYPDSHipay Group DS	0,011 € (-45,00%)	32,76k
NICBSNicox SA	0,0178 € (-22,61%)	11
ALGENGenoway S A Inh Eo 15	3,06 € (-19,69%)	123,45k
ALBOOBOOSTHEAT	0,058 € (-16,91%)	161k
ATOAtos SE	0,0022 € (10,00%)	3,39B
BCPBanco Comercial Portugues SA	0,5124 € (1,03%)	79,14M
ALCYBCybergun	0,0001 € (0,00%)	31,06M
ALVERVergnet	0,0014 € (-6,67%)	21,7M
EDPEDP SA	3,069 € (-1,76%)	12,59M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Pharnext (ALPHA)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Pharnext

ALPHA Neueste Nachrichten

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

ALPHA - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Pharnext (ALPHA) Börsenkurse

Pharnext (ALPHA)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Pharnext

ALPHA Neueste Nachrichten

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

ALPHA - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen